Drugs in ATC Class D07XC

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D07 - CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Up to D07X - CORTICOSTEROIDS, OTHER COMBINATIONS

Drugs in ATC Class: D07XC - Corticosteroids, potent, other combinations

Tradename	Generic Name
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE	betamethasone acetate; betamethasone sodium phosphate
CELESTONE	betamethasone
CELESTONE SOLUSPAN	betamethasone acetate; betamethasone sodium phosphate

D07XC Market Analysis and Financial Projection

The ATC Class D07XC, which encompasses potent corticosteroids combined with other agents for dermatological use, represents a critical segment in the treatment of inflammatory skin conditions. This class includes formulations like betamethasone, desoximetasone, mometasone furoate, and diflucortolone, often paired with keratolytics (e.g., salicylic acid) or antiseptics for enhanced therapeutic efficacy. Below is an analysis of its market dynamics and patent landscape:

---

Market Dynamics

1. Growth Drivers

   • Rising Prevalence of Chronic Skin Disorders: Conditions like psoriasis, eczema, and dermatitis drive demand for potent corticosteroid combinations[10][12][15]. The global corticosteroid-responsive dermatoses market is projected to reach $446.4 million by 2030 (CAGR: 7.4%)[10].
   • Superior Efficacy of Combination Therapies: Combining corticosteroids with agents like salicylic acid improves outcomes for conditions such as psoriasis by addressing inflammation and hyperkeratosis simultaneously[5][7].
   • Expanding Geriatric Population: Older adults are more prone to inflammatory skin conditions, boosting market demand[10][12].

2. Regional Insights

   • North America Dominates: Accounting for 32.6% market share (2023), driven by high healthcare expenditure and advanced R&D infrastructure[15].
   • Asia-Pacific Growth: Rapidly modernizing healthcare systems and increasing disease awareness fuel market expansion[10][12].

3. Key Market Trends

   • Shift Toward Topical Formulations: Over 70% of dermatological corticosteroids are topical[4][6], with D07XC products like mometasone furoate cream widely prescribed for eczema and psoriasis[2][13].
   • Generic Penetration: Mometasone furoate, a leading D07XC drug, faces competition from 25+ suppliers and 27 Drug Master File entries, signaling a robust generic pipeline[2][12].

---

Patent Landscape

1. Dominance of Mometasone Furoate

   • 28 US Patents: Protects formulations, delivery methods, and combination therapies[2][13].
   • Paragraph IV Challenges: Two ongoing litigations highlight its commercial significance[2].
   • Global Patent Families: 47 patents across 12 countries, reflecting extensive innovation[2].

2. Strategic Combinations

   • Patent EP1905451B1 covers mometasone furoate paired with antimuscarinic agents (e.g., tiotropium) for respiratory and dermatological use, underscoring cross-therapeutic applications[3].
   • Antifungal-Corticosteroid Blends: Trials explore combinations with antifungals like terbinafine, expanding indications to fungal-infected dermatitis[7][13].

3. Competitive Pressures

   • Tentative Approvals: A generic nasal spray (0.05 mg/spray) for mometasone furoate is poised to enter the market post-patent expiry[2].
   • Supplier Saturation: 25+ finished product suppliers and 79 bulk API vendors indicate a fragmented yet competitive landscape[2].

---

Clinical and Regulatory Insights

Parameter	Details
Top Marketed Drugs	Mometasone furoate (8 brands), betamethasone (D07XC01), desoximetasone (D07XC02)[1][6][14]
Therapeutic Class	Potent corticosteroids (Group III) with anti-inflammatory and immunosuppressive effects[4][13]
Pipeline Innovations	Phase II trials for nasal polyps and anti-inflammatory combinations[2][9]

---

Challenges and Opportunities

• Safety Concerns: Prolonged use of potent corticosteroids risks skin atrophy and systemic absorption[7][13].
• Emerging Markets: Untapped potential in Asia and Africa for affordable generic formulations[15].
• Combination Therapies: Pairing corticosteroids with biologics (e.g., PDE4 inhibitors) could revolutionize treatment paradigms[9][12].

---

Conclusion

The D07XC class thrives on innovation in combination therapies and strategic patenting, with mometasone furoate leading commercialization efforts. While generics and safety concerns pose challenges, rising global disease burden and R&D investments ensure sustained growth. North America remains pivotal, but Asia-Pacific’s expanding healthcare infrastructure offers lucrative opportunities for market players.

References

1. https://en.wikipedia.org/wiki/ATC_code_D07
2. https://www.drugpatentwatch.com/p/generic-api/MOMETASONE+FUROATE
3. https://data.epo.org/publication-server/rest/v1.2/publication-dates/20100113/patents/EP1905451NWB1/document.pdf
4. https://atcddd.fhi.no/atc_ddd_index/?code=D07C&showdescription=yes
5. https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=D07XC
6. https://pubchem.ncbi.nlm.nih.gov/compound/16-beta-Methyl-1,4-pregnadiene-9-alpha-fluoro-11-beta,17-alpha,21-triol-3,20-dione
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9409645/
8. https://atcddd.fhi.no/atc_ddd_index/?code=D07XC05
9. https://www.towardshealthcare.com/insights/corticosteroids-market-sizing
10. https://www.industryarc.com/Report/15916/corticosteroid-responsive-dermatoses-market.html
11. https://www.metropolitan.co.bw/common_up/metropolitan-health/01-08-2017_BOTSOGO%20HEALTH%20PLAN%20MEDICINE%20PRICE%20LIST%202017.xlsx
12. https://www.gminsights.com/industry-analysis/corticosteroids-market
13. https://go.drugbank.com/drugs/DB14512
14. https://pubchem.ncbi.nlm.nih.gov/compound/Desoximetasone
15. https://market.us/report/corticosteroids-market/